{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:32Z","timestamp":1789997552285,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glutamate carboxypeptidase II (GCP), also known as prostate specific membrane antigen (PSMA) has been found to be expressed in glioma vasculature in in-vitro studies. GCP expression can be traced with the use of [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT used routinely for prostate cancer imaging. The aim of this paper was to analyze GCP expression in the recurrent glial tumors in vivo. 34 patients (pts.) aged 44.5\u2009\u00b1\u200910.3\u00a0years with suspicion of recurrence of histologically confirmed glioma grade III (6 pts.) and grade IV (28 pts.) were included in the study. All patients underwent contrast-enhanced MR and [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT. No radiopharmaceutical-related adverse events were noted. PET\/CT was positive in all the areas suspected for recurrence at MR in all the patients. The recurrence was confirmed by histopathological examinations or follow-up imaging in all cases. The images showed a very low background activity of the normal brain. Median maximal standard uptake value (SUV<jats:sub>max<\/jats:sub>) of the tumors was 6.5 (range 0.9\u201315.6) and mean standard uptake value (SUV<jats:sub>mean<\/jats:sub>) was 3.5 (range 0.9\u20137.5). Target-to-background (TBR) ratios varied between 15 and 1400 with a median of 152. Target-to-liver background ratios (TLR) ranged from 0.2 to 2.6, the median TLR was 1.3. No significant difference of the measured parameters was found between the subgroups according to the glioma grade. High GCP expression in the recurrent glioma was demonstrated in-vivo with the use of [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT. As the treatment options in recurrent glioma are limited, this observation may open new therapeutic perspectives with the use of radiolabeled agents targeting the GCP.<\/jats:p>","DOI":"10.1038\/s41598-021-04613-w","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T11:03:33Z","timestamp":1642071813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging"],"prefix":"10.1038","volume":"12","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Czepczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Koziara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Pe\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"4613_CR1","volume-title":"World Health Organization Histological Classification of Tumours of the Central Nervous System","author":"DN Louis","year":"2016","unstructured":"Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. World Health Organization Histological Classification of Tumours of the Central Nervous System 4th edn. (International Agency for Research on Cancer, 2016).","edition":"4"},{"key":"4613_CR2","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","volume":"135","author":"AG Wernicke","year":"2011","unstructured":"Wernicke, A. G. et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch. Pathol. Lab. Med. 135, 1486\u20131489 (2011).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"4613_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2867-14-26","volume":"14","author":"N Nomura","year":"2014","unstructured":"Nomura, N. et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 14, 26 (2014).","journal-title":"Cancer Cell Int."},{"issue":"30","key":"4613_CR4","doi-asserted-by":"publisher","first-page":"14498","DOI":"10.1016\/S0021-9258(18)47823-4","volume":"262","author":"MB Robinson","year":"1987","unstructured":"Robinson, M. B., Blakely, R. D., Couto, R. & Coyle, J. T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 262(30), 14498\u201314506 (1987).","journal-title":"J. Biol. Chem."},{"key":"4613_CR5","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S1462399409000969","volume":"11","author":"R Zhao","year":"2009","unstructured":"Zhao, R., Matherly, L. H. & Goldman, I. D. Membrane transporters and folate homeostasis: Intestinal absorption and transport into systemic compartments and tissues. Expert. Rev. Mol. Med. 11, e4 (2009).","journal-title":"Expert. Rev. Mol. Med."},{"key":"4613_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1107\/S090744490700902X","volume":"63","author":"JR Mesters","year":"2007","unstructured":"Mesters, J. R., Henning, K. & Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta. Crystallogr. D Biol. Crystallogr. 63, 508\u2013513 (2007).","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"key":"4613_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF02815236","volume":"31","author":"LA Passani","year":"1997","unstructured":"Passani, L. A., Vonsattel, J. P., Carter, R. E. & Coyle, J. T. N-Acetylaspartylglutamate, N-Acetylaspartate, and N-Acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer\u2019s diseases. Mol. Chem. Neuropathol. 31, 97\u2013118 (1997).","journal-title":"Mol. Chem. Neuropathol."},{"key":"4613_CR8","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1111\/jcmm.15350","volume":"24","author":"J Tanjore Ramanathan","year":"2020","unstructured":"Tanjore Ramanathan, J. et al. Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain. J. Cell Mol. Med. 24, 6916\u20136927 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"4613_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber, M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 56, 668\u2013674 (2015).","journal-title":"J. Nucl. Med."},{"key":"4613_CR10","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar, A. et al. Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors\u2014Preliminary analysis. Clin. Nucl. Med. 42, e41\u2013e48 (2017).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","volume":"138","author":"M Matsuda","year":"2018","unstructured":"Matsuda, M. et al. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J. Neurooncol. 138, 581\u2013589 (2018).","journal-title":"J. Neurooncol."},{"key":"4613_CR12","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1097\/RLU.0000000000002175","volume":"43","author":"A Sasikumar","year":"2018","unstructured":"Sasikumar, A. et al. Utility of 68Ga-PSMA-11 PET\/CT in imaging of glioma\u2014A pilot study. Clin. Nucl. Med. 43, e304\u2013e309 (2018).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR13","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/RLU.0000000000002668","volume":"45","author":"F Marafi","year":"2020","unstructured":"Marafi, F., Sasikumar, A., Fathallah, W. & Esmail, A. 18F-PSMA 1007 brain PET\/CT imaging in glioma recurrence. Clin. Nucl. Med. 45, e61\u2013e62 (2020).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR14","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1097\/RLU.0000000000002520","volume":"44","author":"P Verma","year":"2019","unstructured":"Verma, P. et al. Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients. Clin. Nucl. Med. 44, e318\u2013e322 (2019).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR15","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","volume":"42","author":"RA Salas Fragomeni","year":"2017","unstructured":"Salas Fragomeni, R. A. et al. Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas. Clin. Nucl. Med. 42, e433\u2013e435 (2017).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00259-018-3934-2","volume":"45","author":"J Kunikowska","year":"2018","unstructured":"Kunikowska, J., Kr\u00f3licki, B. & Kr\u00f3licki, L. Glioblastoma multiforme: Another potential application for 68Ga-PSMA PET\/CT as a guide for targeted therapy. Eur. J. Nucl. Med. Mol. Imaging. 45, 886\u2013887 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"4613_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov225.24","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson, B. M. et al. Consensus recommendations for a standarized brain tumor imaging protocol in clinical trials. Neuro Oncol. 17, 1188\u20131198 (2015).","journal-title":"Neuro Oncol."},{"key":"4613_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/RLU.0000000000002806","volume":"45","author":"J Kunikowska","year":"2020","unstructured":"Kunikowska, J., Kuli\u0144ski, R., Muylle, K., Koziara, H. & Kr\u00f3licki, L. 68Ga-prostate-specific membrane antigen-11 PET\/CT: a new imaging option for recurrent glioblastoma multiforme?. Clin. Nucl. Med. 45, 11\u201318 (2020).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","volume":"46","author":"L Kr\u00f3licki","year":"2019","unstructured":"Kr\u00f3licki, L. et al. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur. J. Nucl. Med. Mol. Imaging. 46, 614\u2013622 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"4613_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1073\/pnas.93.2.749","volume":"93","author":"RE Carter","year":"1996","unstructured":"Carter, R. E., Feldman, A. R. & Coyle, J. T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 93, 749\u2013753 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4613_CR21","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192\u20133198 (1999).","journal-title":"Cancer Res."},{"key":"4613_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia, P. et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using multiple tumour tissue microarray technique. Histopathology 50, 472\u2013483 (2007).","journal-title":"Histopathology"},{"key":"4613_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/(SICI)1099-1492(199704)10:2<73::AID-NBM448>3.0.CO;2-4","volume":"10","author":"PJ Pouwels","year":"1997","unstructured":"Pouwels, P. J. & Frahm, J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 10, 73\u201378 (1997).","journal-title":"NMR Biomed."},{"key":"4613_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0006-8993(88)90243-0","volume":"456","author":"LC Williamson","year":"1988","unstructured":"Williamson, L. C. & Neale, J. H. Ultrastructural localization of N-acetylaspartylglutamate in synaptic vesicles of retinal neurons. Brain Res. 456, 375\u2013381 (1988).","journal-title":"Brain Res."},{"issue":"1\u20132","key":"4613_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-4781(98)00200-0","volume":"1443","author":"DS O'Keefe","year":"1998","unstructured":"O\u2019Keefe, D. S. et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta. 1443(1\u20132), 113\u2013127 (1998).","journal-title":"Biochim. Biophys. Acta."},{"key":"4613_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/abr.abr_209_18","volume":"8","author":"P Mahzouni","year":"2019","unstructured":"Mahzouni, P. & Shavakhi, M. Prostate-specific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv. Biomed. Res. 8, 18 (2019).","journal-title":"Adv. Biomed. Res."},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.30699\/ijp.13.1.45","volume":"13","author":"H Saffar","year":"2018","unstructured":"Saffar, H., Noohi, M., Tavangar, S. H., Saffar, H. & Azimi, S. Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade. Iran J. Pathol. 13, 45\u201353 (2018).","journal-title":"Iran J. Pathol."},{"key":"4613_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00259-014-2921-5","volume":"42","author":"J Schwenck","year":"2015","unstructured":"Schwenck, J. et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur. J. Nucl. Med. Mol. Imaging. 42, 170\u2013171 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"4613_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/RLU.0000000000002398","volume":"44","author":"S Kebir","year":"2019","unstructured":"Kebir, S., Weber, M. & Lazaridis, L. Hybrid 11C-MET PET\/MR combined with \u201cmachine learning\u201d in glioma diagnosis according to the revised glioma WHO classification 2016. Clin. Nucl. Med. 44, 214\u2013220 (2019).","journal-title":"Clin. Nucl. Med."},{"issue":"9","key":"4613_CR30","doi-asserted-by":"publisher","first-page":"14603","DOI":"10.1038\/s41598-019-50182-4","volume":"2019","author":"J Lohmeier","year":"2019","unstructured":"Lohmeier, J. et al. Quantitative biparametric analysis of hybrid 18F-FET PET\/MR-neuroimaging for differentiation between treatment response and recurrent glioma. Sci. Rep. 2019(9), 14603 (2019).","journal-title":"Sci. Rep."},{"key":"4613_CR31","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1097\/RLU.0000000000002280","volume":"43","author":"RA Salas Fragomeni","year":"2018","unstructured":"Salas Fragomeni, R. A., Pienta, K. J., Pomper, M. G., Gorin, M. A. & Rowe, S. P. Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in cerebral radionecrosis: Implications for diagnostic imaging of high-grade gliomas. Clin. Nucl. Med. 43, e419\u2013e421 (2018).","journal-title":"Clin. Nucl. Med."},{"key":"4613_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-18-1233","volume":"25","author":"S Jiang","year":"2019","unstructured":"Jiang, S. et al. Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: A validation study with image-guided stereotactic biopsy. Clin. Cancer Res. 25, 552\u2013561 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4613_CR33","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","volume":"27","author":"BRJ van Dijken","year":"2017","unstructured":"van Dijken, B. R. J., van Laar, P. J., Holtman, G. A. & van der Hoorn, A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur. Radiol. 27, 4129\u20134144 (2017).","journal-title":"Eur. Radiol."},{"key":"4613_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","volume":"47","author":"J Kunikowska","year":"2020","unstructured":"Kunikowska, J. et al. Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617. Eur. J. Nucl. Med. Mol. Imaging. 47, 1605\u20131606 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"4613_CR35","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur. J. Nucl. Med. Mol. Imaging. 46, 2536\u20132544 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04613-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:51:01Z","timestamp":1669323061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04613-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"652"}}